PISCATAWAY, N.J., July 31, 2025 /PRNewswire/ -- GenScript Biotech Corporation (HK.1548), a leading global provider of life science research and manufacturing services, today announced that...
Peak Energy's solution is the first battery energy storage system to remove nearly all moving parts with new patent-pending technology, driving significant cost-savings
DENVER, July...
NEW YORK, July 31, 2025 /PRNewswire/ -- Authenticom, a leading provider of secure, vendor-neutral data integration and hygiene solutions for the automotive industry, has been...
Mountain View Top Ranked Community Hospital and #2 Overall in San Jose Metro Area
MOUNTAIN VIEW, Calif., July 31, 2025 /PRNewswire/ -- El Camino Health...
According to Towards Chemical and Materials, the global green building materials market volume was valued at 600 million tons in 2024 and is predicted to hit around 1,271.6 million tons by 2034 growing at a CAGR of 7.80% from 2025 to 2034. North America dominated the green building materials market with a market share of 31.14% in 2024.
According to Towards Chemical and Materials, the global green building materials market volume was valued at 600 million tons in 2024 and is predicted to hit around 1,271.6 million tons by 2034 growing at a CAGR of 7.80% from 2025 to 2034. North America dominated the green building materials market with a market share of 31.14% in 2024.
MONTREAL, July 30, 2025 /CNW/ - In light of the widespread suffering, loss of human life, and growing international calls for an immediate and lasting...
20 Distinguished Awardees to Be Honored During ANSI Innovation Summit in Rockville, MD
NEW YORK, July 30, 2025 /PRNewswire/ -- The American National Standards Institute (ANSI) announced...
TOKYO and CAMBRIDGE, Mass., July 30, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that the two-year real-world study in the U.S of lecanemab (generic name, product name: LEQEBMI®), an anti-Aβ protofibril* antibody, was presented at the Alzheimer's Association International Conference (AAIC) 2025, held in Toronto, Canada and virtually. Only lecanemab fights AD in two ways – targeting both amyloid plaque and protofibrils*, which can impact tau downstream.